Page 2 - Hammersmith Functional Motor Scale Expanded News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass. (BUSINESS WIRE) Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play

United kingdomFrance generalDennis riedlJay backstromTed mylesAriane lovellTraceym saccoRushmie nofsingerScholar rock incSociety for immunotherapy of cancerDrug administrationExchange commissionScholar rock holding corporationEuropean medicines agencyScholar rockChief executive officer

Nusinersen May Stabilize Disease Status in SMA Types 2 and 3

Treatment with nusinersen may decrease disease progression in pediatric patients who are nonambulatory with spinal muscular atrophy types 2 and 3.

Orphanet journalHammersmith functional motor scale expandedRevised upper limb module

Scholar Rock Reports Positive Trends in Phase 2 Study of Therapy for Non-ambulatory SMA2 and SMA3 Patients

Scholar Rock Reports Positive Trends in Phase 2 Study of Therapy for Non-ambulatory SMA2 and SMA3 Patients
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesComunidad autonoma de catalunaJay backstromInternational scientific congressEuropean medicines agencyDrug administrationRevised hammersmith scalePediatric evaluationDisability inventory computer adaptive testEndurance shuttle boxBlock testRevised upper limb moduleHammersmith functional motor scale expandedFast trackOrphan drugRare pediatric disease

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomComunidad autonoma de catalunaJay backstromAriane lovellRushmie nofsingerBasil darrasScholar rock incInternational scientific congressDrug administrationHarvard medical schoolExchange commissionEuropean medicines agencyAssociate neurologist in chiefBoston childrenChief executive officer

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA - Scholar Rock Holding (NASDAQ:SRRK) - Press Release

- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indic

United statesComunidad autonoma de catalunaJay backstromBasil darrasScholar rock incInternational scientific congressDrug administrationHarvard medical schoolExchange commissionEuropean medicines agencyAssociate neurologist in chiefBoston childrenChief executive officerPediatric evaluationDisability inventory computer adaptive testReported outcome measurement information system